What about non-oral methods of contraception e.g
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months

Still, to pave the way for more widespread clinical applications of gut-based interventions, future research will need to shift emphasis on more reward phases and clinical populations, ideally using larger samples with publication of the associations regardless of their threshold as full maps and regardless of a potential confirmation or rejection of the hypothesized action on reward responses
Novo Nordisk A/S Pfizer, Inc
This, therefore, answers the next question
[1] [3] Gastrointestinal side effects are among the most frequently reported adverse reactions associated with Ozempic therapy